Risankizumab demonstrates effectiveness in achieving steroid-free clinical remission in the real-world cohort of patients ...
Sumitomo Pharma America, Inc. (SMPA) today announced that it has enrolled the required number of participants in its pivotal Phase 2 monotherapy trial for enzomenib, an investigational, oral selective ...
Both Tal-DP and Tal-D yielded longer progression-free survival than DPd in those who had received at least one line of therapy ...
Eighteen patients underwent allo-HSCT after CAV (Supplementary Table 3). The median time from completion of CAV to initiate conditioning chemotherapy for transplantation was 17 (1–90) days. At the ...
Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R2 ) data across subgroups in this ...
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor ...
Triplet therapy with pirtobrutinib, venetoclax and rituximab as a two-year fixed-duration therapy improves progression-free survival for patients with relapsed/refractory chronic lymphocytic leukemia ...
An expert discusses the expanded treatment options for refractory ITP, emphasizing accurate diagnosis, combination therapies targeting platelet production and destruction, and the evolving role of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results